Axsome Therapeutics (AXSM) Net Equity Issued and Repurchased (2017 - 2026)

Axsome Therapeutics (AXSM) has 10 years of Net Equity Issued and Repurchased data on file, last reported at $6.3 million in Q1 2026.

• For the quarter ending Q1 2026, Net Equity Issued and Repurchased fell 67.72% year-over-year to $6.3 million; the trailing twelve-month figure through Mar 2026 stood at $54.6 million (up 11.04% YoY), and the FY2025 full-year result was $67.9 million, up 66.5% from the prior year.
• Net Equity Issued and Repurchased grew to $6.3 million in Q1 2026, from $5.7 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $211.3 million in Q2 2023 to a low of $5.7 million in Q4 2025.
• A 5-year average of $49.4 million and a median of $25.3 million in 2022 frame the typical range for Net Equity Issued and Repurchased.
• Across the five-year window, Net Equity Issued and Repurchased jumped 2868.62% in 2022 and tumbled 81.27% in 2023, its largest moves.
• Tracing AXSM's Net Equity Issued and Repurchased over 5 years: stood at $180.2 million in 2022, then plunged by 81.27% to $33.8 million in 2023, then plunged by 51.35% to $16.4 million in 2024, then tumbled by 65.44% to $5.7 million in 2025, then gained by 11.77% to $6.3 million in 2026.
• Business Quant data shows AXSM's Net Equity Issued and Repurchased at $6.3 million in Q1 2026, $5.7 million in Q4 2025, and $9.9 million in Q3 2025.